Previous close | 44.07 |
Open | 44.89 |
Bid | 44.76 x 0 |
Ask | 45.33 x 0 |
Day's range | 44.56 - 44.89 |
52-week range | 25.41 - 48.42 |
Volume | |
Avg. volume | 32 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The mobile version of Valorant, a popular first-person shooter from Riot, which is based in the US but owned by Tencent Holdings, is among the titles approved on Wednesday by the National Press and Publication Administration (NPPA), the agency in charge of licensing video games in China. Under Chinese regulations, an overseas video game cannot be monetised in the country without a government permit. Getting approval often involves localisation with censorship of sensitive content and it must be operated through a Chinese partner - often Tencent and NetEase, the country's two largest video gaming companies.
The best China stocks include Tesla archrival BYD as well as messaging and gaming giant Tencent and e-commerce leader PDD Holdings.
Tencent-backed artificial intelligence (AI) drug researcher QuantumPharm is raising up to HK$1.13 billion (US$144.5 million) in a Hong Kong initial public offering (IPO) from Tuesday, eyeing the first listing under a new regime for pre-revenue specialist technology firms that was introduced more than a year ago. The Shenzhen-headquartered company, also known as XtalPi, is offering 187.37 million shares at HK$5.03 to HK$6.03 each. The shares will start trading on June 13. QuantumPharm is one of o